NCT00622713已完成4 期
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 228
- 试验地点
- 1
- 主要终点
- Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study
研究概览
简要总结
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State Examination 10-26) in the community setting
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males, and females of at least 50 years old with a primary caregiver
- •Probable Alzheimer's disease
- •Mini-Mental State Examination (MMSE) score of ≥ 10 and ≤ 26
- •Patients initiating therapy for the first time with a Cholinesterase (ChE) inhibitor (patients prescribed both rivastigmine and memantine are allowed) or patients who failed to benefit from previous ChE inhibitor treatment
- •Residing with someone in the community throughout the study or, if living alone, in contact with the responsible caregiver everyday
排除标准
- •Patients not treated according to the product monograph for capsules
- •Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application)
- •History of allergy to topical products containing any of the constituents of the patches
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Percentage of Patients Who Achieved and Maintained the Maximum Dose of 10 cm^2 Rivastigmine Patch for at Least 8 Weeks During 24 Weeks Study
时间窗: 24 weeks
The primary endpoint was the percentage of patients who were able to tolerate (and stay on for at least 8 weeks) rivastigmine target patch size 10 cm\^2.
次要结局
- Clinical Global Impression of Change (CGI-C) by Physician(Baseline and week 24)
- Mean Change From Baseline to Week 24 in the 4-item Instrumental Activities of Daily Living (4-IADL) Score(Baseline to week 24)
- Mean Change From Baseline to Week 24 in the Mini-Mental State Examination (MMSE) Score(Baseline to week 24)
- Mean Change From Baseline to Week 24 in the Mini-Zarit Inventory Score(Baseline to week 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT06745622Haisco Pharmaceutical Group Co., Ltd.47
终止
3 期
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT01123707Otsuka Pharmaceutical Development & Commercialization, Inc.173
已完成
2 期
PF-06741086 Long-term Treatment in Severe HemophiliaHemophilia A or BNCT03363321Pfizer20
已完成
2 期
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisAlpha-MannosidosisNCT01681940Zymenex A/S10
终止
4 期
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial LipoatrophyHIV-Associated LipodystrophyHIV InfectionsNCT00126308Kirby Institute100